Luminex Corporation (LMNX)
-NasdaqGS | Prev Close: | 20.39 |
|---|
| Open: | N/A |
|---|
| Bid: | 16.01 x 1000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 19.07 |
|---|
| Beta: | 0.79 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 15.39 - 25.75 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 184,142 |
|---|
| Market Cap: | 847.96M |
|---|
| P/E (ttm): | 130.71 |
|---|
| EPS (ttm): | 0.16 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why GenMark Diagnostics Shares Slumpedat Motley Fool(Tue, Jun 18)
- Luminex Collaborates with NMTCZacks(Fri, Jun 14)
- Luminex's CEO Presents at Goldman Sachs Healthcare Conference Call Transcriptat Seeking Alpha(Tue, Jun 11)
- GenMark down 7% after Natural Molecular launches new productat theflyonthewall.com(Tue, Jun 11)
- Natural Molecular launch a positive for Luminex, says Leerinktheflyonthewall.com(Tue, Jun 11)
- Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporation's xMAP TechnologyPR Newswire(Tue, Jun 11)
- Why Luminex May Be About to Take Offat Motley Fool(Fri, Jun 7)
- Luminex and Merck KGaA Extend TiesZacks(Fri, May 31)
- Luminex coverage assumed with a Hold at Jefferiestheflyonthewall.com(Fri, May 31)
- Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution AgreementPR Newswire(Tue, May 28)
- Luminex's CEO Presents at UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Tue, May 21)
- In Insider Trading, Tesla Motors Sees a Sale While MoSys CEO Buys SharesMinyanville(Tue, May 21)
- Monday 5/20 Insider Buying Report: LMNX, GFFat Forbes(Mon, May 20)
- LUMINEX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Mon, May 20)
- Genomic Health Director Buys More Than 52K Shares and 4 Insider Trades to Noteat Wall St. Cheat Sheet(Fri, May 17)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| LMNX | 0.00% | 847.96M |
| BAX | 0.00% | 37.75B |
| COV | 0.00% | 29.91B |
| CSRT.L | 0.08% | 229.60M |
| BDX | 0.00% | 19.19B |
Key Statistics
| Forward P/E (1 yr): | 36.41 |
|---|
| P/S (ttm): | 4.10 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.31 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.10 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | 1.23 |
|---|
Business Summary
Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products for the life sciences and diagnostic industries.
View More